Susan Haigney

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

The European Medicines Agency (EMA) announced on July 25, 2025 that its Committee for Medicinal Products for Human Use (CHMP) has approved a change in the existing gas propellant used in budesonide/glycopyrronium/formoterol fumarate (BGF, Trixeo Aerosphere and Riltrava Aerosphere) (1,2). The propellant may be replaced with a low global warming potential (GWP) gas alternative that has a 1000-fold reduction in GWP, 99.9% lower than currently used. BGF will be the first inhaled drug in the European Union to use the new low GWP propellant, according to EMA.

The new formulation is the first pMDI to use the low global warming potential (GWP) gas alternative.

New propellant has a 1000-fold reduction in GWP.

High GWP propellants, such as hydrofluorocarbon gases, are being phased out to comply with the EU regulation regarding 

fluorinated greenhouse gases (EU Regulation 2024/573)

BGF is used as a fixed-dose triple-combination maintenance therapy for adults with moderate-to-severe chronic obstructive pulmonary disease (COPD). The usual dose is two inhalations twice daily using a pressurized metered-dose inhaler (pMDI). The propellant used in pMDIs is a liquified compressed gas that generates an aerosol cloud to deliver the API to the patient through inhalation. These propellants that are typically high GWP, such as hydrofluorocarbon gases, are being phased out to comply with the EU regulation regarding 

New formulation is therapeutically equivalent to existing formulation

AstraZeneca AB, the drug’s marketing authorization holder, focused on a lower GWP propellant for the reformulation, which uses the same API and dose characterized in guideline requirements (4). CHMP’s positive opinion was based on results from the next-generation propellant clinical development program, according to AstraZeneca (2). The new formulation of BGF was found to be therapeutically equivalent to the current product, according to EMA (1). The company plans to transition more of its pMDI portfolio to the new propellant by 2030.

“Respiratory medicines delivered by pressurized metered-dose inhalers are essential for millions of people living with respiratory diseases in Europe, including specific vulnerable populations such as children and the elderly,” Frederik Trinkmann, professor and senior pulmonologist at the Thoracic Clinic at Heidelberg University Hospital, Germany, said in the press release (2). “The transition of Trixeo to the propellant with near-zero Global Warming Potential ensures clinicians’ treatment decisions can focus on clinical needs while also supporting environmental goals.” 

“The CHMP positive opinion of Trixeo Aerosphere with the next-generation propellant allows us to address the needs of both patients and the planet and is a significant milestone in our commitment to delivering innovations for sustainable healthcare in the EU,” Ruud Dobber, executive vice president, BioPharmaceuticals Business Unit, AstraZeneca, said in the release. “Starting with Trixeo, the transition to the near-zero Global Warming Potential propellant across our pressurized metered-dose inhaled respiratory medicines is an important step towards achieving our Ambition Zero Carbon strategy.”

Susanna Palkonen, director of the European Federation of Allergy and Airways Diseases Patients' Associations, added, “COPD is a devastating disease and the third-leading cause of mortality in the world. People living with COPD need access to a treatment which is right for them as well as a healthy environment and clean air. We welcome the positive opinion from the CHMP for the inhaled respiratory medicine containing the next-generation propellant with a significantly reduced carbon footprint.”

EMA. First Reformulation of an Inhaled Medicine with Environmentally Friendly Gas Propellant. Press Release. July 25, 2025. 

https://www.ema.europa.eu/en/news/first-reformulation-inhaled-medicine-environmentally-friendly-gas-propellant

AstraZeneca. Trixeo Aerosphere Receives Positive EU CHMP Opinion as First Inhaled Medicine Using Next-Generation Propellant with Near-Zero Global Warming Potential. Press Release. July 25, 2025. 

https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-receives-positive-eu-chmp-opinion-first-inhaled-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html

EU. EUR-Lex. Regulation (EU) 2024/573 of the European Parliament and of the Council of 7 February 2024 on Fluorinated Greenhouse Gases, Amending Directive (EU) 2019/1937 and Repealing Regulation (EU) No 517/2014. Eur-lex.europa.eu. Feb. 20, 2024 (accessed July 25, 2025). 

https://eur-lex.europa.eu/eli/reg/2024/573/oj/eng

EMA. Guideline on the Requirements for Demonstrating Therapeutic Equivalence Between Orally Inhaled Products (OIP) for Asthma and Chronic Obstructive Pulmonary Disease (COPD) (EMA, July 14, 2025). 

https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-demonstrating-therapeutic-equivalence-between-orally-inhaled-products-oip-asthma-chronic-obstructive-pulmonary-disease-copd-revision-2_en.pdf

Articles

The European Medicines Agency has approved a new low global warming potential (GWP) propellant for the inhaled drug budesonide/glycopyrronium/formoterol fumarate (BGF), marking a significant environmental advancement. This reformulation, which maintains therapeutic equivalence to the existing product, aligns with EU regulations on fluorinated greenhouse gases. AstraZeneca plans to transition more of its pressurized metered-dose inhaler (pMDI) portfolio to this eco-friendly propellant by 2030. This initiative supports sustainable healthcare while addressing the needs of patients with chronic obstructive pulmonary disease (COPD).

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava Aerosphere that will have a 1000-fold reduction in global warming potential compared to the current propellant.

EMA Approves Lower GWP Alternative for Inhalation Medicine

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

AstraZeneca announced on July 21, 2025, that it will invest $50 billion in manufacturing and R&D facilities in the United States by 2030. The company expects the investment to support its goal of reaching $80 billion in revenue by 2030, half of which will be generated in the US.

Investment includes a multi-billion-dollar drug substance manufacturing facility in Virginia focused on chronic diseases.

The company will expand R&D capabilities in Maryland and Massachusetts.

The investments are part of AstraZeneca’s plan to reach $80 billion in total revenue by 2030, 50% of which is planned to be generated in the US.

Among the facilities will be a multi-billion-dollar manufacturing facility in Virginia to specialize in treatments for chronic diseases. The facility, set to be the company’s largest single manufacturing investment, will produce AstraZeneca’s weight management and metabolic portfolio (e.g., oral GLP-1, baxdrostat, oral PCSK9), small molecules, peptides, and oligonucleotides.

During the next five years, the company also plans on expanding its R&D facility in Gaithersburg, Maryland; building a R&D center in Cambridge, Massachusetts; and expanding R&D for novel medicines. New manufacturing facilities will include cell therapy facilities in Rockville, Maryland and Tarzana, California. The company will expand continuous manufacturing capabilities at its Mount Vernon, Indiana facility and specialty manufacturing at its Coppell, Texas facility. New sites for the supply of clinical trial materials are also planned.

“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,” Pascal Soriot, chief executive officer, AstraZeneca, said in a press release (1). “It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology and will strengthen the country’s domestic supply chain for medicines.”

“For decades Americans have been reliant on foreign supply of key pharmaceutical products,” Howard Lutnick, US Secretary of Commerce, said in the press release (1). “President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”

Governor Glenn Youngkin, Commonwealth of Virginia, added (1), “I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth.”

Building on previous US manufacturing investment

This new investment is in addition to the $3.5 billion US expansion the company announced in November 2024 (2) for an R&D center in Cambridge, Massachusetts; a biologics manufacturing facility in Maryland; and specialty manufacturing capabilities in Texas.

“Our multi-billion-dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States,” Soriot said in a press release at the time of the announcement (2). “By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”

AstraZeneca Plans to Invest $50 Billion in America for Medicines Manufacturing and R&D

2. AstraZeneca. AstraZeneca Invests $3.5 Billion in R&D and Manufacturing in the United States. Press Release. Nov. 12, 2024.

The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as well as facilities in California, Indiana, Maryland, Massachusetts, and Texas.

AstraZeneca to Invest $50 Billion in US Manufacturing and R&D

FDA announced on July 21, 2025 that George Francis Tidmarsh, MD, PhD has been appointed the new director of the agency’s Center for Drug Evaluation and Research (CDER), which is tasked with ensuring the safety and efficacy of drugs in the United States (1). Tidmarsh has more than 30 years of experience in biotechnology, clinical medicine, and regulatory science.

Tidmarsh attended Stanford University where he earned a degree in medicine and a PhD in cancer biology, as well as completing a residency in pediatrics. He also completed two subspecialty programs at Stanford in pediatric oncology and neonatology and is the founding co-director of Stanford’s Master of Translational Research and Applied Medicine (M-TRAM) program. M-TRAM trains students and researchers on how to translate scientific research into real-world application.

“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development—from bench to bedside,” said FDA Commissioner Marty Makary. “His appointment to lead CDER brings exceptional scientific, regulatory, and operational expertise to the agency. I look forward to working with him to strengthen our drug review programs, foster innovation, and advance cross-agency initiatives that improve health outcomes for the American public.”

A founder and CEO of multiple biopharmaceutical companies over the years, including La Jolla Pharmaceutical Company and Horizon Pharma, Tidmarsh has been involved with the clinical development of seven FDA-approved drugs from discovery through approval (2). Unlike previous CDER directors, Tidmarsh lacks previous experience in government, but has served as an expert on FDA panels (3).

It is speculated that Tidmarsh may play a role in reassessing FDA’s approach to prescription drug advertising (4). According to Bloomberg, Tidmarsh has expressed concerns about inconsistencies by FDA regarding the regulation “long-standing restrictions on off-label communication by manufacturers and questioned some vaccine makers’ ads during the pandemic” (4). Tidmarsh, according to Bloomberg, has also expressed concerns about fraud in academic science and funds a program supporting investigation of scientific fraud (4).

Tidmarsh has served on advisory boards across academia, government, and industry and has authored 143 scientific publications and patents.

“It is good to see a scientist and physician with phenomenal experience like Dr. Tidmarsh at the helm of CDER,” Aloka Srinivasan, a member of 

®’s Editorial Advisory Board, and principal and managing partner of Raaha LLC, said of the appointment. “Dr. Tidmarsh understands how the pharmaceutical industry operates and the roadblocks to better treatment of many diseases. As a former FDA employee and a member of the pharmaceutical industry, I hope that he is able to change the culture of the office he is heading, and incorporate better understanding of their role, which, other than just approving drugs is to see the bigger picture and understand how the approval of a drug may affect the American public."

Former CDER director retired in January 2025

CDER’s previous director, Patrizia Cavazzoni, resigned in January 2025. She started with FDA as deputy director of operations of CDER and served as acting principal deputy commissioner of Food and Drugs briefly in 2019. In 2021, she was made the director of CDER.

“While I could spend a lot of time enumerating our achievements, I want to highlight our biggest success: our people and our culture,” Cavazzoni said in a letter to her colleagues at the time of her retirement. “As I leave CDER, I can say with confidence that the Center is at its strongest. We have hired and retained record numbers of the best scientists and professionals. We have built a cohort of world-class managers and executives who are solidly at the helm of our organization and will continue to lead CDER. And most important of all, we created a culture that fosters respect for one another, inclusion, accountability, and diversity of thought and life experience. Our culture is what makes us strong and resilient, and it’s the foundation of what we have accomplished and will accomplish in the future” (5).

FDA. Stanford Faculty Member George Tidmarsh, MD, PhD Named Director of Center for Drug Evaluation and Research. Press Release. July 21, 2025. 

https://www.fda.gov/news-events/press-announcements/stanford-faculty-member-george-tidmarsh-md-phd-named-director-center-drug-evaluation-and-research

Joseph, A. FDA Taps Biotech Veteran George Tidmarsh to Lead Drug Center. 

https://www.statnews.com/2025/07/21/george-tidmarsh-fda-marty-makary-drug-center-director/

Samorodnitsky, D. FDA’s CDER Gets New Chief in Biopharma Veteran George Tidmarsh. 

Langreth, R. and Hornblower, S. FDA Appoints Biotech Executive as Top Drug Regulator Under RFK Jr. 

Haigney, S. Cavazzoni Retires as CDER Director. 

https://www.pharmtech.com/view/cavazzoni-retires-as-cder-director

George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine program, has been appointed as the new director of the Center for Drug Evaluation and Research.

FDA Appoints New CDER Director, George Tidmarsh

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have issued recommendations through the 

Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)

 for securing the supply of anti-D immunoglobulins used to prevent RhD immunization during pregnancy in the European Union. The supply is in trouble because the number of plasma donors has declined. Donors with anti-D immunoglobulins are the only source for manufacturing these drugs, according to EMA, and these treatments are the only option to prevent RhD immunization during pregnancy.

Supply of anti-D immunoglobulins used to prevent RhD immunization during pregnancy is at risk in the EU. The number of immunized donors is limited and there is a decline in existing donors.

EMA’s drug shortages steering group recommends EU Member States to create plans to secure the supply of anti-D immunoglobulins in the EU that include safety, legal, ethical, and regulatory considerations.

Industry is encouraged to invest in manufacturing capacity and development of alternatives to plasma-derived anti-D immunoglobulins.

PhD immunization occurs, according to EMA, when a pregnant person with RhD-negative blood is exposed to RhD-positive blood from the fetus growing in their body. A potentially fatal immune reaction may result from the exposure and impact the health of the fetus as well as after the baby is born (1).

During their assessment, MMSG identified the following key vulnerabilities in the supply chain (2):

The number of immunized donors was limited and there was a decline in existing donors.

There were challenges in the collection, manufacturing, and pooling of small plasma batches.

Global capacity was constrained by a limited number of marketing authorization holders and centers collecting plasma for anti-D immunoglobulins.

There was a dependency on countries outside of the EU for supply of plasma for these products.

Recommendations for regulators, industry, and other stakeholders

MMSG issued recommendations to national regulators, the European Commission, the plasma industry, and research organizations. The new recommendations are for EU Member States to create plans to secure the supply of anti-D immunoglobulins in the EU that include safety, legal, ethical, and regulatory considerations. Reducing unnecessary use through procedures such as non-invasive prenatal screening should be focused on. Alternative treatments should also be researched and developed. Communication campaigns about plasma-derived medicinal products should also be implemented.

The recommendations also state, “Member States, in collaboration with experts, including learned societies, patient organizations, and other relevant stakeholders should develop national guidelines to facilitate prioritization of patients who require these medicines during shortage situations, where necessary. The MSSG may coordinate the development of a Union level prioritization plan to manage critical shortages, coordinated at Union level” (2).

EMA stated in the press release that the EC should identify measures to ensure the supply of these treatments and coordinate with EU Member States (1). “Policy measures set out in the proposed Critical Medicines Act could be leveraged, such as joint procurement of manufacturing services to establish or increase supply of these medicines to the EU,” the agency stated in the release. The recommendations document says the EC should also “facilitate cooperation between key stakeholders, including national competent blood authorities and national competent medicines authorities to ensure coherence across relevant legislative frameworks.”

Industry is also being encouraged to ensure the supply of these treatments in Europe by investing in manufacturing capacity and development of alternatives to plasma-derived anti-D immunoglobulins.

The recommendations (2) state that the plasma industry and research organizations should “collaborate with Member States and the European Commission to identify effective mechanisms to support plasma collection and use. Consider initiatives and tools implemented by regulatory authorities to secure the supply of anti-D immunoglobulins and where needed, provide relevant data necessary for identifying and developing these mechanisms.”

EMA. Strengthening Supply Chain of Anti-D Immunoglobulins. Press Release. July 4, 2025. 

https://www.ema.europa.eu/en/news/strengthening-supply-chain-anti-d-immunoglobulins

EMA. Recommendations of the Executive Steering Group on Shortages and Safety of Medicinal Products to Address Anti-D Immunoglobulin Supply Chain Vulnerabilities. EMA/135603/2025. June 23, 2025. 

https://www.ema.europa.eu/en/documents/other/recommendations-executive-steering-group-shortages-safety-medicinal-products-address-anti-d-immunoglobulin-supply-chain-vulnerabilities_en.pdf

The agency’s Executive Steering Group on Shortages and Safety of Medicinal Products has issued recommendations to address vulnerabilities in the supply chain of anti-D immunoglobulins.

EMA Moves to Secure Supply of Critical Drugs Used During Pregnancy

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

FDA announced on June 27, 2025, that Sandoz, Inc. is voluntarily recalling one lot of cefazolin for injection, USP, 1 gram per vial after customers complained that four penicillin G potassium for injection, USP, 20 million units labeled vials were incorrectly included in a carton of Cefazolin for Injection vials (1). While the company states it has not received any reports of adverse events associated with the recall, they did receive one complaint of the wrong product being given to a patient.

Four vials of penicillin G potassium for injection, USP were wrongly included in a lot of cefazolin for Injection, USP.

The two antibiotics have different indications. Using penicillin G potassium for injection, USP instead of cefazolin for injection, USP could be life threatening.

Sandoz’s new facility in Slovenia will produce injectable products for both existing and upcoming biosimilars.

The new facility is part of a $1.1 billion investment the company has planned through 2029.

The impacted lot number is PG4360, vial national drug code (NDC) number 0781-3451-70, with an expiration date of 2027-NOV (1). The lot was manufactured by Sandoz GmbH and distributed by Sandoz Inc. The vials that were incorrectly included have the vial NDC 0781-6136-94 and an expiration date of 2027-NOV.

The two antibiotics have different indications

Cefazolin for injection USP is indicated for the treatment and/or prevention of bacterial infections in different parts of the body in adults, the elderly, and children (1). Penicillin G potassium for injection treats certain serious infections, such as septicemia, skin infections, and wound infections, and can be used to treat diphtheria, community-acquired pneumonia, peritonitis, meningitis/brain abscesses, osteomyelitis, infections of the genital tract, anthrax, tetanus, gas gangrene, listeriosis, pasteurellosis, rat bite fever, fusospirochetes, actinomycosis, complications in gonorrhea and syphilis, and Lyme. It should be used to only treat or prevent infections caused by susceptible bacteria to reduce the chance of drug-resistant bacterial from developing.

According to an FDA press release (1), the two antibiotics have different indications despite being part of the same beta-lactam group of antibiotics and having overlapping patient populations. The dosing regimens for each may also differ.

Administration of penicillin G potassium injection instead of cefazolin injection may have life-threatening consequences that include lack of efficacy resulting in less than optimal treatment of severe infections, antibiotic resistance, allergic reactions, drug interactions, and cardiac arrhythmias caused by high potassium.

Sandoz is asking customers to return the recalled product, which was shipped to select wholesalers for nationwide distribution. The company recommends providers stop using the product immediately. Adverse events may be reported to FDA through its 

In other Sandoz news, the company broke ground on a new facility in Slovenia in July that will produce injectable products for both existing and upcoming biosimilars. The project adds $440 million to a $1.1 billion investment the company has planned through 2029.

"Biosimilars is the fastest-growing segment of our pipeline as the need of patients and healthcare systems for these critical medicines continues to grow rapidly,” Richard Saynor, chief executive officer of Sandoz, said in a press release (2). “As the global leader in the field, we are investing to meet rapidly growing patient demand. With a commitment of over US$1.1 billion, we are proud to significantly expand our biosimilar manufacturing capacity in Europe as Slovenia’s largest direct foreign investor. This is another major step that will position Sandoz uniquely to capitalize on the unprecedented biosimilars market opportunity of the next decade."

"Our investment in biomanufacturing in the heart of Europe marks another important milestone in building our own independent manufacturing network—one that enhances our control, resilience and agility across the global supply chain,” Glenn Gerecke, chief manufacturing and supply officer at Sandoz, said in the release. “We recognize the strategic value Slovenia brings for us as a company: a highly skilled talent pool in natural sciences and engineering; a central location with world-class logistics infrastructure; cost-competitive production; and a stable, innovation-driven environment closely connected to academia and research."

FDA. Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Cefazolin for Injection Due to Product Mispackaging. Press Release. June 27, 2025. 

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-nationwide-recall-one-lot-cefazolin-injection-due-product-mispackaging

Sandoz. Sandoz Further Asserts Leadership in Biosimilars, Breaking Ground on New Slovenia Facility to Expand European Biosimilar Hub and Global Market Reach. Press Release. July 1, 2025. 

https://www.sandoz.com/sandoz-further-asserts-leadership-biosimilars-breaking-ground-new-slovenia-facility-expand-european/

The company is voluntarily recalling one lot of cefazolin for injection, USP, 1 gram per vial due to customer complaints of the wrong product being included in a carton.

Sandoz Recalls Cefazolin Due to Mispackaging, Opens Biosimilar Facility in Slovenia

Hikma Pharmaceuticals USA announced on June 28, 2025 that it is investing $1 billion by 2030 to expand its generic-drug R&D and manufacturing capabilities in its Ohio and New Jersey, United States, facilities. The company has invested $4 billion in the past 15 years to expand its US operations, which began in 1991, and now has an annual domestic capacity to produce 12 billion finished doses of generic medicines.

"We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," Hafrun Fridriksdottir, president, Hikma Rx, said in a press release (1). "Hikma and our 2300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.”

“Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines with more than 180 injectable products in our portfolio and a growing pipeline,” Bill Larkins, president, Hikma Injectables, added. “This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients.”

Investment in affordability and community

“As a pharmacist and chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It’s important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today,” US Rep. Buddy Carter, R-Ga., said in the release.

“Hikma continues to invest in American workers, and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans’ access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete,” US Rep. Mike Carey, R-Ohio, said in the release.

In other company news, Hikma published its 2024 Sustainability Report, detailing the company’s approach to sustainability.

"Access to medicines remains at the heart of everything we do at Hikma," said Tim Brooks, the company’s vice-president of Sustainability, in a press release (2). "This sustainability report highlights our belief that providing high-quality medicines is not just our business—it's our responsibility to our people, customers, healthcare professionals, patients and the communities we serve around the world. This year, we have further reinforced access to medicine as the core of our sustainability strategy by leveraging our strong manufacturing presence and working with stakeholders across the healthcare ecosystem.

“This key objective is supported by our commitment to our people, our planet, and our suppliers. Additionally, we have introduced metrics for each of these areas to demonstrate our performance and ensure sustainability remains embedded throughout our corporate strategy,” Brooks added.

Hikma Pharmaceuticals USA Announces $1 Billion of New US Investment to Further Expand its Domestic Manufacturing and Development of Essential Generic Medicines

Hikma Publishes its 2024 Sustainability Report Reinforcing Commitment to Global Access to Medicines

Acting Responsibly. Hikma Sustainability Report 2024.

The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.